Critical Comparison: MeiraGTx (MGTX) & Its Competitors

MeiraGTx (NASDAQ:MGTX) is one of 846 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare MeiraGTx to related companies based on the strength of its risk, valuation, analyst recommendations, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares MeiraGTx and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
MeiraGTx Competitors	-12,283.59%	-195.39%	-30.85%

Volatility & Risk

MeiraGTx has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, MeiraGTx’s competitors have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares MeiraGTx and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MeiraGTx	$81.39 million	-$114.20 million	13.63
MeiraGTx Competitors	$715.89 million	$12.16 million	-14.86

MeiraGTx’s competitors have higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for MeiraGTx and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	0	2.62
MeiraGTx Competitors	9904	15278	45630	1595	2.54

MeiraGTx presently has a consensus price target of $24.00, indicating a potential upside of 147.93%. As a group, “Biotechnology” companies have a potential upside of 120.42%. Given MeiraGTx’s stronger consensus rating and higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than its competitors.

Summary

MeiraGTx beats its competitors on 7 of the 13 factors compared.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.